Boya Bio-Pharmaceutical Group Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
1,444
- Stock Symbol
-
300294
- Investments
-
5
- Share Price
-
$3.94
- (As of Friday Closing)
Boya Bio-Pharmaceutical Group General Information
Description
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.
Contact Information
Website
www.china-boya.comCorporate Office
- No.333, Huiquan Road
- High-tech Industrial Park
- Fuzhou, Jiangxi 344000
- China
Corporate Office
- No.333, Huiquan Road
- High-tech Industrial Park
- Fuzhou, Jiangxi 344000
- China
Boya Bio-Pharmaceutical Group Stock Performance
As of 14-Mar-2025, Boya Bio-Pharmaceutical Group’s stock price is $3.94. Its current market cap is $1.99B with 504M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.94 | $3.90 | $3.70 - $5.98 | $1.99B | 504M | 4.18M | $0.05 |
Boya Bio-Pharmaceutical Group Financials Summary
As of 30-Sep-2024, Boya Bio-Pharmaceutical Group has a trailing 12-month revenue of $238M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,858,174 | 1,694,884 | 2,021,268 | 2,829,956 |
| Revenue | 237,764 | 374,844 | 409,635 | 410,484 |
| EBITDA | 31,728 | 59,569 | 89,606 | 80,709 |
| Net Income | 25,926 | 33,565 | 64,176 | 53,357 |
| Total Assets | 1,163,377 | 1,104,435 | 1,164,346 | 1,195,742 |
| Total Debt | 658 | 3,450 | 5,125 | 5,583 |
Boya Bio-Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Boya Bio-Pharmaceutical Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Boya Bio-Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Boya Bio-Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Boya Bio-Pharmaceutical Group Investments & Acquisitions (5)
Boya Bio-Pharmaceutical Group’s most recent deal was a Merger/Acquisition with Green Cross Hong Kong Holdings for . The deal was made on 17-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Green Cross Hong Kong Holdings | 17-Jul-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Hainan Tianhuang Pharmaceutical | 14-Aug-2017 | Merger/Acquisition | Pharmaceuticals | ||
| Jiangxi Huiyinbi | 01-Jan-2017 | Merger/Acquisition | Pharmaceuticals | ||
| Guizhou Tianan Pharmaceutical | 26-Aug-2015 | Secondary Transaction - Private | Pharmaceuticals | ||
| Guizhou Tianan Pharmaceutical | 30-Dec-2013 | Merger/Acquisition | Pharmaceuticals |
Boya Bio-Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
35.52 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 421
Rank
Percentile
Boya Bio-Pharmaceutical Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Guizhou Tianan Pharmaceutical | Guiyang, China | 1986 |
Boya Bio-Pharmaceutical Group FAQs
-
When was Boya Bio-Pharmaceutical Group founded?
Boya Bio-Pharmaceutical Group was founded in 1993.
-
Where is Boya Bio-Pharmaceutical Group headquartered?
Boya Bio-Pharmaceutical Group is headquartered in Fuzhou, China.
-
What is the size of Boya Bio-Pharmaceutical Group?
Boya Bio-Pharmaceutical Group has 1,444 total employees.
-
What industry is Boya Bio-Pharmaceutical Group in?
Boya Bio-Pharmaceutical Group’s primary industry is Biotechnology.
-
Is Boya Bio-Pharmaceutical Group a private or public company?
Boya Bio-Pharmaceutical Group is a Public company.
-
What is Boya Bio-Pharmaceutical Group’s stock symbol?
The ticker symbol for Boya Bio-Pharmaceutical Group is 300294.
-
What is the current stock price of Boya Bio-Pharmaceutical Group?
As of 14-Mar-2025 the stock price of Boya Bio-Pharmaceutical Group is $3.94.
-
What is the current market cap of Boya Bio-Pharmaceutical Group?
The current market capitalization of Boya Bio-Pharmaceutical Group is $1.99B.
-
What is Boya Bio-Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Boya Bio-Pharmaceutical Group is $238M.
-
What is Boya Bio-Pharmaceutical Group’s annual earnings per share (EPS)?
Boya Bio-Pharmaceutical Group’s EPS for 12 months was $0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
